{"name":"Percheron Therapeutics","slug":"percheron-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNR0IyS3hKbkRhSzlOZXFMZzA5TVBtZWVtbVd1cG9KR0Q3WGZxMkpGSHR0VThNdXp6RFY1eEJESmxRQXNsR0tiRnJwa3llcnc4VVRZYS1GWFVjSUtQTTBlUWFKS1dvaFloZDNWdGxUOHBidTg5VkZnaVBHQ2JmSkJDTXlabHR3dkItZmc4a0dPUEZzZkowV3c?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com","headline":"Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBscVlhT2h4SlJvZTB4dDFZa1lRYjdYQW1ZWVhUb3BDS1lzZHRVNmY1ZFJ5aEZGcFVqZEgwYmlDbnd0SWhyLXN0bzlCOUhJOUpPcGJjTDlMaGhFRkltdFJHTmo2aGtFX2VtRVRjSGgyRQ?oc=5","date":"2026-02-17","type":"pipeline","source":"VISTA.Today","summary":"Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - VISTA.Today","headline":"Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQYzdKaDRjcWlYVi1kbkpNLUU5WXFEb0tCbGNOWHJRMUp6bnQ1a1FmV2JackpCb3RBSk9hbVF3VjVIYlhFMm5Ld2xtREJjaVBsSkxoclF5YUt6cTZwRjhhNWpOcGQ0WU9fZFpZSmhmVG10dHJvZVEyOG5oODdpNjh3RnhHcG1ZM3FHeVdTSnliNE1HcjdRMjJwa1llSndEYVFETlFheDlfV3dVZzUtOTJPd2tzYW95MzNCamkwejB4RHRxelU4ZVdGNG4wNEN3ZVpQTUtpeDhn?oc=5","date":"2026-02-07","type":"trial","source":"Proactive financial news","summary":"HMBD-002: Percheron’s immunotherapy enters Phase II planning - ICYMI - Proactive financial news","headline":"HMBD-002: Percheron’s immunotherapy enters Phase II planning - ICYMI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE02ZkZuaXhWR2ZIWG5WOUc4OWFUTkhuMXAtb24xdHh4dWRqZTc4Q2pOZlNNcXBVMWlJaW41WFJfOEZNMXh6NlRPRTJ5U1M4YXRn?oc=5","date":"2025-10-30","type":"pipeline","source":"smallcaps.com.au","summary":"Insights: Percheron Therapeutics Ltd (ASX:PER) - smallcaps.com.au","headline":"Insights: Percheron Therapeutics Ltd (ASX:PER)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNVGlja05RZXhlRHBOaGNzTkZFd1B1eFJESGFWckxRQlU0N0xtYmtWVTYyTktHTXVRaE52c1RGYzRwa3lWX3d4RHFfOXMybVFfVC00UUk4S3o5Y3E1a2VsOGpqRzRpLWdMYWk4NlFiM1RLdktLV0RlR2xDRkxlYWJRcmFjTWF4QmdQeUJsWERXUHhJZXFCRnNMMUVJQ3NwdlNWakd3Z1lWU3JuTU5qRklqOTNYZDZla2dyRXRPM2tLWDRHQjJMYkVlOE5ma3FIcElkc2xSelJUa1hRMGU3RTlQbFVINHlkT2wwazhaTEFR?oc=5","date":"2025-08-01","type":"deal","source":"Proactive financial news","summary":"Percheron Therapeutics reports progress in immuno-oncology pipeline, licensing deals - Proactive financial news","headline":"Percheron Therapeutics reports progress in immuno-oncology pipeline, licensing deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOZm1RdVlmUU4yaHR1em9hS3NLdGxDaTNST0tmT09KcXRsMDVlUk1vRHdIMWpaODdlX21YS0x6dlpzeDl5MFM1dmRSTzNROGlFQWYtU1Z5Rmx2cjlBTThROU5MNGpjNWoyNmNkZGZMN01pNm5GR0FmQjBHSmVVWXR3b1ZsZkV4emJybnBCNGJYaw?oc=5","date":"2025-07-08","type":"deal","source":"Oncology Pipeline","summary":"Licensing analysis: big deals bolster biotech - Oncology Pipeline","headline":"Licensing analysis: big deals bolster biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1kOGMyQmxjX2VJUFpjSkQ0enRTcEdSVUhuVXI3NVJ3UzI3SEdzX1hJcUVpUVNZMndtb2F2eFhQSkNzaTBJZ0o5SERmZVpJQ0FiUkl5bTFPQ0JOc3ZfcUgwc04temtZOFkzOU8yOVhxaXhpcnBPU0E?oc=5","date":"2025-07-07","type":"pipeline","source":"Stocks Down Under","summary":"Percheron Therapeutics (ASX:PER) picks itself up in 2025 - Stocks Down Under","headline":"Percheron Therapeutics (ASX:PER) picks itself up in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQS041aHlmZGxQVnZjbG1sZkgwYmYxak12TDk5NFBxZi16WHliREtYLUQ2dXR2Z3R2MVY0OTJEV21qdEJxbmE4M1c3TllpX3Z5eU1VWldtUF9VSGJkRkh5eEtCVjNBRF83dEZUTkZwUFJ1LWhfVXZQeWdUU1RMWDUwLWxGLTZQcmp2Y2dnWUpORUtXMzA3TDVRLXlUV3dNTklmcjkzV2MwbXc4Z1k?oc=5","date":"2025-06-26","type":"trial","source":"Fierce Biotech","summary":"Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug - Fierce Biotech","headline":"Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNcWRDcl9nUHRvd19JT0JvNEZMcjdMQll4VmtuUjQ0YUwyOFlhZlpKcFNJZXFjNUlzaVV2RjI1ZTNURTRfQVh5cjR5d0ctbG1IckZNcXFIV0NrNDhMVGpLS0xnRk5vZkZlaDNQTTU2MkVhQWhGYVhnc0J2SXotRDlvUzBkdWlCd3F2YmIwX2NWelduM1pyRnhkbjhNdmhlNjE3T29QMi1pSjFPZVBfNnJuaU1WcFZYWURQTW5VbkJUc1V2MmkxYnU0NWxSMHJIV3hiQnRpWU5CSm9NSGo4NnVUZEtSX0xGamVPYlA5cDRjOGNPVTZxRlJHSGNGRHk3SlhZOGhQVzR0d2M2dHpld3FNVnZ3?oc=5","date":"2025-06-25","type":"trial","source":"globenewswire.com","summary":"Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready - globenewswire.com","headline":"Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxORXhPQlpwVlFvY0hJM016R0hXbWpVWUdybVlwNmpFTXZpVUEtd1c2ZXRGdF9ZT0l5UUpaMnRJTzJKRFVRS2w1YU1wT0VqUzBBRlJCVWh0MFZ3cDlqT1FEdjBqcmV0eVlmS3IyVlBEeWRiN25DTldPN1p5aDh1QllDME1yVXA5SkJFcEphOENZeklSdjRhZmxZa3JRX01xQUJ6RjI2ZkRFTDFlSUxCS0MtcEhhNmstdDJLZjZYLTVCcnR4XzJzY0JFM1RkMEpBa0VLcVBaQ0F3M1lsaUp4d195S3FFaHRxMmJheEFDZ29Tb0doR1V3d3c?oc=5","date":"2025-02-23","type":"deal","source":"Proactive financial news","summary":"Percheron Therapeutics proposes to in-license new drug program for rare neurological disease - Proactive financial news","headline":"Percheron Therapeutics proposes to in-license new drug program for rare neurological disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQUkpoU2ZWVHNRYkJ0OHpqbmdqYjJyRndJTENWSkZwN0p6LVBYS0hiaVdqR3laaXh0cGNUazZGQllhSmNVYmdoYkQzdXRJQ3d4aTNTMWRCVlZZUTJTY1B0bjN3Tm5YeUFyWVA4eHpKaHMtMmJSbTRwamliT2dvUlVGbDRGWHhWQlpNOFd1dGNSNC1STm51WGk2V094QkxTZzU2T0pjQU1JSnZCdXlmTVI2V0Fn?oc=5","date":"2025-01-06","type":"trial","source":"Clinical Trials Arena","summary":"Percheron plans to broaden pipeline following avicursen disappointment - Clinical Trials Arena","headline":"Percheron plans to broaden pipeline following avicursen disappointment","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQN3dPZkNyYmtySndxUHN3WGRVUmZ3RXQzNnlnLUdUemczcFlyeFVlMFVlb0FBWHA5YWNjTGc5dGFESnZtUEN4MkNJOXRGcmtEMTJKSFNYWEp6RHl2YWlFRUZNTW5kWTZZemNtUVVPMFZJWC13R0pHOVhPMEltekVMaWZhMkxzaFRPWFVWOG5tSDBqZVA5bnpNX0dR?oc=5","date":"2024-10-10","type":"pipeline","source":"Yahoo Finance","summary":"Analysts Expect Breakeven For Percheron Therapeutics Limited (ASX:PER) Before Long - Yahoo Finance","headline":"Analysts Expect Breakeven For Percheron Therapeutics Limited (ASX:PER) Before Long","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}